

Systemic Therapy Update



BC Cancer Agency

CARE + RESEARCH

An agency of the Provincial Health Services Authority

May 2018
Volume 21, No. 5

For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Editor's Choice** – Highlights of Changes in Protocols, PPPO and Patient Handouts
- **Systemic Therapy Update** – New Look Coming Soon!
- **Cancer Drug Manual** – New: Olaratumab; Revised: Busulfan, Irinotecan
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts:** Revised: GIAJFFOX, GIAJFL, GIAVDOC, GIAVFL, GIEFFOXRT, GIFFIRB, GIFFOXB, UGIFFOXPAN, GIFIRINOX, GIFOLFIRI, GIFOLFOX, GIGAJFFOX, GIGAVEOCAP, UGIGFLODOC, GIGFOLFIRI, GIRAJFFOX, LUAVDC, LUAVDOC, LUAVNP, LUAVPEM, LUAVPG, ULUAVPMTN, LUAVVIN, LYEPOCHR, UMYCARDEX, UMYCARLD, SAAJGI, SAAVGI, SAAVGIDD
- **Website Resources and Contact Information**

EDITOR'S CHOICE

HIGHLIGHTS OF CHANGES IN PROTOCOLS, PROVINCIAL PRE-PRINTED ORDERS (PPPO) AND PATIENT HANDOUTS

All BC Cancer Protocols and PPPOs are in the process of undergoing a number of general updates and changes to address miscellaneous issues. Such changes include updating the documents with the new institutional name and logo, and to accommodate the necessary revisions to support the building of the Computerized Physician Order Entry (CPOE) system in the Clinical and Systems Transformation (CST) project. These revisions include standardization of baseline tests, laboratory tests panels (e.g. liver function or enzyme tests, electrolytes), administration time of drugs, etc.

SYSTEMIC THERAPY UPDATE

NEW LOOK COMING SOON!

The Systemic Therapy Update will be updated shortly to reflect the new BC Cancer logo and institutional colours. As part of this process, the Editorial Board is also reviewing the esthetics and formatting of the newsletter to enhance the readership experience, both online and in print. We are looking to you to provide us feedback on what changes you prefer to see (e.g. page layout, viewing experience online vs. in print, colour and font size of text and subheadings, colour of background, etc.). Please forward your feedback to: bulletin@bccancer.bc.ca.

NEW MONOGRAPHS AND PATIENT HANDOUTS

Olaratumab Interim Monograph has been developed. Olaratumab is a novel targeted recombinant human immunoglobulin G monoclonal antibody that specifically binds to the platelet-derived growth factor receptor-alpha (PDGFR α), thus inhibiting receptor activation by PDGF ligands. Disrupting the PDGFR α pathway in tumour cells has been shown to inhibit cell proliferation and tumour growth. The usual dosing is 15 mg/kg given intravenously on days 1 and 8, in a three-week cycle. Please note that olaratumab is not a BC Cancer benefit drug and requires submission to the BC Cancer Compassionate Access Program (CAP).

Highlights from this document include:

- Severe and life-threatening infusion reactions have occurred with the first administration of olaratumab; premedicate all patients for cycle one (days 1 and 8) with intravenous H₁ antagonist and corticosteroid
- The most serious adverse events reported in clinical trials included infusion-related reactions, anemia, abnormal hepatic function, tumour hemorrhage, syncope and deep vein thrombosis
- When given in combination with doxorubicin, there were higher rates and severity of adverse events normally attributed to doxorubicin (neutropenia, mucositis, nausea, diarrhea and fatigue) compared to when doxorubicin was given alone.

REVISED MONOGRAPHS AND PATIENT HANDOUTS

Highlights of key changes and/or updates to the Monographs and Patient Handouts are listed below:

Busulfan Monograph and Chemo Chart:

- *Supply and Storage* – added new supplier; removed products no longer available in Canada
- *Solution Preparation and Compatibility* – included information about line flushing

Irinotecan Monograph and Chemo Chart:

- *Cautions* – updated information about risks of prior and concurrent radiation
- *Special Populations* – included statement about elderly patients having low tolerance for side effects
- *Supply and Storage* – removed products no longer available in Canada

LIST OF REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatment requiring BC Cancer Compassionate Access Program approval are prefixed with the letter “U”.

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)					
CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
GIAJFFOX	☑	☑	☑	<i>Dose Banding and various minor updates</i>	Adjuvant Combination Chemotherapy for Stage III and Stage IIB Colon Cancer Using Oxaliplatin, Fluorouracil, and Leucovorin
GIAJFL	☑	☑	☑	<i>Dose Banding and various minor updates</i>	Adjuvant Therapy of Colon Cancer Using Fluorouracil Injection and Infusion, and Leucovorin Infusion
GIAVDOC	☑	☑	☑	<i>Institutional Name and Side Effects Management updated, Tests, Diluent Size, Dose Modifications clarified</i>	Palliative Treatment of Metastatic Esophagogastric Adenocarcinoma with Docetaxel
GIAVFL	☑	☑	☑	<i>Dose Banding and various minor updates</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Fluorouracil Injection and Infusion, and Leucovorin Infusion
GIEFFOXRT	☑	☑	☑	<i>Dose Banding and various minor updates</i>	Combined Modality Therapy for Locally Advanced Esophageal Cancer using Oxaliplatin, Fluorouracil, Leucovorin, and Radiation Therapy
GIFFIRB	☑	☑	☑	<i>Dose Banding and various minor updates</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Fluorouracil, Leucovorin, and Bevacizumab
GIFFOXB	☑	☑	☑	<i>Dose Banding and various minor updates</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Fluorouracil, Leucovorin, and Bevacizumab
UGIFFOXPAN	☑	☑	☑	<i>Dose Banding and various minor updates</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Fluorouracil, Leucovorin, and Panitumumab
GIFIRINOX	☑	☑	☑	<i>Dose Banding and various minor updates</i>	Palliative Combination Chemotherapy for Advanced Pancreatic Adenocarcinoma Using Irinotecan, Oxaliplatin, Fluorouracil, and Leucovorin

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)					
CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
GIFOLFIRI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Dose Banding and various minor updates</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Irinotecan, Fluorouracil and Leucovorin
GIFOLFOX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Dose Banding and various minor updates</i>	Palliative Combination Chemotherapy for Metastatic Colorectal Cancer Using Oxaliplatin, Fluorouracil, and Leucovorin
GIGAJFFOX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Dose Banding and various minor updates</i>	Adjuvant Chemotherapy of Gastric Cancer Patients with D2 Resection (Node Negative) or Ineligible for Adjuvant Chemoradiation Using Oxaliplatin, Fluorouracil, and Leucovorin
GIGAVEOCAP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Institutional name updated, Tests clarified</i>	Palliative Therapy for Metastatic or Locally Advanced Gastric or Esophagogastric Cancer Using Epirubicin, Oxaliplatin and Capecitabine
UGIGFLODOC	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Institutional Name and Side Effects Management updated, Tests, Diluent Size, Dose Modifications clarified</i>	Perioperative Treatment of Resectable Adenocarcinoma of the Stomach, Gastroesophageal Junction or Lower 1/3 Esophagus using Docetaxel, Oxaliplatin, Infusional Fluorouracil, and Leucovorin
GIGOLFIRI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Dose Banding and various minor updates</i>	Second-Line Palliative Combination Chemotherapy for Metastatic Gastric or Esophageal Adenocarcinoma Using Irinotecan, Fluorouracil, and Leucovorin
GIRAJFFOX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<i>Dose Banding and various minor updates</i>	Adjuvant Combination Chemotherapy for Stage III Rectal Cancer Using Oxaliplatin, Fluorouracil, and Leucovorin
LUAVDC	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests clarified</i>	First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Cisplatin and Docetaxel
LUAVDOC	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests and Dose Modifications clarified, Contact Physician and Institutional Name updated</i>	Second or Later-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Docetaxel
LUAVNP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests and Dose Modifications clarified</i>	Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) with Cisplatin and Vinorelbine
LUAVPEM	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Premedications and Dose Modifications clarified</i>	Second-Line Chemotherapy of Advanced Non-Small Cell Lung Cancer (NSCLC) With Pemetrexed

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED)

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
LUAVPG	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests and Dose Modifications clarified</i>	Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Platinum and Gemcitabine
ULUAVPMTN	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Premedications and Dose Modifications clarified</i>	Maintenance Therapy of Advanced Non-Small Cell Lung Cancer (NSCLC) With Pemetrexed
LUAVVIN	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Tests and Dose Modifications clarified</i>	Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) with Vinorelbine in Elderly Patients
LYEPOCHR	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<i>Rituximab Administration clarified</i>	Treatment of Lymphoma with Dose-Adjusted Etoposide, Doxorubicin, Vincristine, Cyclophosphamide, Prednisone and Rituximab with Intrathecal Methotrexate
UMYCARDEX	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Diluent Volume clarified</i>	Therapy of Multiple Myeloma Using Carfilzomib and Dexamethasone With or Without Cyclophosphamide
UMYCARLD	<input type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Diluent Volume clarified</i>	Therapy of Multiple Myeloma Using Carfilzomib, Lenalidomide with Dexamethasone
SAAJGI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Institutional Name updated, Tests clarified</i>	Adjuvant Treatment of C-Kit Positive High Risk Gastrointestinal Stromal Cell Tumours Using Imatinib
SAAVGI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Institutional Name updated, Tests clarified</i>	Treatment of Advanced c-Kit Positive and c-Kit Negative Gastrointestinal Stromal Cell Tumors (GIST's) Using Imatinib
SAAVGIDD	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Institutional Name updated, Tests clarified</i>	Treatment of Advanced c-Kit Positive Gastrointestinal Stromal Cell Tumors (GIST's) Using 800 mg Dosing of Imatinib

WEBSITE RESOURCES AND CONTACT INFORMATION

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor	604-877-6000 x 673028		bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604-877-6275		druginfo@bccancer.bc.ca
Nurse Educators	604-877-6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604-675-8003 Toll Free 888-675-8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	604-877-6000 x 672247		mclin@bccancer.bc.ca
Provincial Professional Practice Nursing			BCCancerPPNAdmin@ehcnet.phsa.ca
OSCAR	888-355-0355	604-708-2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604-877-6277	604-708-2026	cap_bcca@bccancer.bc.ca
Pharmacy Oncology Certification	250-712-3900 x 686820		rxchemocert@bccancer.bc.ca
BC Cancer-Abbotsford	604-851-4710 Toll Free 877-547-3777		
BC Cancer-Prince George (Centre for the North)	250-645-7300 Toll Free 888-775-7300		
BC Cancer-Surrey	604-930-2098 Toll Free 800-523-2885		
BC Cancer-Kelowna	250-712-3900 Toll Free 888-563-7773		
BC Cancer-Vancouver	604-877-6000 Toll Free 800-663-3333		
BC Cancer-Victoria	250-519-5500 Toll Free 800-670-3322		

EDITORIAL REVIEW BOARD

Sally Waignein, PharmD (Editor)
 Mario de Lemos, PharmD, MSc (Oncol)
 Mark Goodwin, MLIS
 Jagbir Kaur, RN, MN

Caroline Lohrisch, MD
 Judi Piper-Wallace, BSN
 Alison Pow, BSc(Pharm)